Floatz logo

Inno-206

Colorectal Cancer Metastatic

Northwell HealthPhase 4 / ApprovedActive
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
65/ 100

Competitive context

64 Active assets in the Colorectal Cancer Metastatic cohort.

Asset / SponsorPhaseRating
Binimetinib
Pierre Fabre Medicament
Phase 3BB
Irinotecan
Oncolytics Biotech
Phase 4BB
Aflibercept
Sanofi
Phase 3BB
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Centre Georges Francois Leclerc
Phase 2B
Durvalumab
University of Iowa
Phase 2B

View all 50 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →